Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial

Ivo N. van Schaik, Vera Bril, Nan van Geloven, Hans-Peter Hartung, Richard A. Lewis, Gen Sobue, John-Philip Lawo, Michaela Praus, Orell Mielke, Billie L. Durn, David R. Cornblath, Ingemar S. J. Merkies, PATH Study Grp

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)35-46
Number of pages12
JournalLancet Neurology
Volume17
Issue number1
DOIs
Publication statusPublished - 1 Jan 2018

Keywords

  • QUALITY-OF-LIFE
  • PRIMARY ANTIBODY DEFICIENCIES
  • IGG SELF-INFUSIONS
  • MUSCLE STRENGTH
  • THERAPY
  • POLYRADICULONEUROPATHY
  • CIDP
  • HOME
  • ICE
  • SATISFACTION

Cite this

van Schaik, I. N., Bril, V., van Geloven, N., Hartung, H-P., Lewis, R. A., Sobue, G., Lawo, J-P., Praus, M., Mielke, O., Durn, B. L., Cornblath, D. R., Merkies, I. S. J., & PATH Study Grp (2018). Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurology, 17(1), 35-46. https://doi.org/10.1016/S1474-4422(17)30378-2